Company Name, Ticker, Customers, else..

Point Biopharma Global Inc (NASDAQ: PNT)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Point Biopharma Global Inc 's

Name: Point Biopharma Global Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PNT Sales vs. its Competitors Q3 2023

Comparing the current results to its competitors, Point Biopharma Global Inc reported Revenue increase in the 3 quarter 2023 by 0 % year on year.
The revenue growth was below Point Biopharma Global Inc 's competitors' average revenue growth of 22.45 %, achieved in the same quarter.

• List of PNT Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Point Biopharma Global Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< PNT Stock Performance Comparisons

<< See the full list of PNT competitors

*Market share is calculated based on total revenue.

News about Point Biopharma Global Inc Contracts

A Paradigm Shift in Prostate Cancer Treatment: Positive SPLASH Trial Results and POINT Biopharma's Resilient Growth

December 18, 2023

In the field of oncology, breakthroughs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have remained a significant challenge. However, recent reports from Lantheus and POINT Biopharma reveal a beacon of hope for patients with this aggressive form of prostate cancer. The positive topline results of the phase 3 SPLASH trial utilizing 177Lu-PNT2002 have shown a statistically significant improvement in radiographic progression-free survival (rPFS). This groundbreaking development is poised to revolutionize the treatment landscape for mCRPC patients.
Lantheus and POINT Biopharma Collaboration:
Lantheus and POINT Biopharma have jointly conducted the phase 3 SPLASH tri...

PNT's Stock Performance relative to its Competitors

Publicly Traded Peers of Point Biopharma Global Inc

Y mabs Therapeutics inc
Share Performance

+8.03%

This Year

Y mabs Therapeutics inc

Profile

Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.

More about Y mabs Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 390.188 mill.	$ 84.721 mill.	$ -22.223 mill.

Alaunos Therapeutics Inc
Share Performance

-50.61%

This Year

Alaunos Therapeutics Inc

Profile

Alaunos Therapeutics Inc is a biotechnology company that operates on a research and development business model. Their focus is on discovering and developing innovative therapies for various diseases and medical conditions. Through their scientific expertise and collaborations, they aim to bring novel treatments to market to improve patient outcomes.

More about Alaunos Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3.939 mill.	$ - mill.	$ -4.010 mill.

60 Degrees Pharmaceuticals Inc
Share Performance

-49.00%

This Year

60 Degrees Pharmaceuticals Inc

Profile

60 Degrees Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of innovative treatments for infectious diseases, particularly malaria.

More about 60 Degrees Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2.794 mill.	$ 1.111 mill.	$ -8.112 mill.

Spero Therapeutics Inc
Share Performance

-2.44%

Over The Past 5 Days

Spero Therapeutics Inc

Profile

Spero Therapeutics Inc's business model focuses on developing novel antibiotics to combat drug-resistant bacterial infections.

More about Spero Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 68.738 mill.	$ 61.186 mill.	$ 15.235 mill.

Sio Gene Therapies Inc
Share Performance

+22.88%

30 Days

Sio Gene Therapies Inc

Profile

Sio Gene Therapies Inc operates with a business model focused on developing and commercializing gene therapies to treat and potentially cure various neurological genetic diseases. Their approach involves leveraging cutting-edge gene therapy technology to address unmet medical needs and improve patients' quality of life.

More about Sio Gene Therapies Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 35.360 mill.	$ - mill.	$ -28.829 mill.

40 more competitors available

Sources: Point Biopharma Global Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, August 31, 2026 3:00 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Point Biopharma Global Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.